---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-005460"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-01-23T23:59:59+00:00"
generated_at: "2026-05-27T14:02:24.185959+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Verastem exercises option for exclusive ex-Asia rights to KRAS G12D inhibitor VS-7375

## Summary
- Exercised GenFleet option on Jan 14, 2025 for VS-7375, an oral, selective KRAS G12D (ON/OFF) inhibitor.
- Rights cover worldwide development and commercialization outside mainland China, Hong Kong, Macau, and Taiwan.
- Updated corporate presentation posted Jan 23, 2025; no specific financial or pipeline data disclosed in filing.

## SEC filing metadata
- accession: 0001104659-25-005460
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925005460/0001104659-25-005460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925005460/tm254144d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-005460
- JSON: https://secwatch.observer/filing/0001104659-25-005460.json
- Plain text: https://secwatch.observer/filing/0001104659-25-005460.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.